ESC 365 - SGLT2 inhibitors and heart failure: expensive diuretics or added value?

ESC Premium Access

SGLT2 inhibitors and heart failure: expensive diuretics or added value?

Session: SGLT2 inhibitors and cardiovascular outcomes

Topic: Diabetes and the Heart

Speaker: Doctor M. Kosiborod (Kansas City, US)

Event: ESC CONGRESS 2019

Congress Presentation

About the speaker

Doctor Mikhail Kosiborod

St. Luke's Mid America Heart Institute, Kansas City (United States of America)

24 presentations

1 follower

3 more presentations in this session

SGLT2 inhibitors and atherosclerosis-related outcomes: the good and the bad

Speaker: Professor A. Norhammar (Stockholm, SE)

SGLT2 inhibitors: is the benefit related to renal outcomes?

Speaker: Professor A. Ceriello (Milan, IT)

Panel discussion: how should cardiologists use SGLT2 inhibitors in clinical practice?

Access the full session

SGLT2 inhibitors and cardiovascular outcomes

Speakers: Doctor M. Kosiborod, Professor A. Norhammar, Professor A. Ceriello

About the event

ESC CONGRESS 2019

31 August - 4 September 2019

Sessions Presentations

Congress

Related content

ESC Premium Access

Who should be treated with an SGLT2 inhibitor?

30 August 2021

ESC Premium Access

SGLT2 Inhibitors in heart failure.

29 August 2021

ESC 365 is supported by